Alnylam Pharmaceuticals
ALNY
#1122
Rank
A$29.70 B
Marketcap
A$221.78
Share price
-0.51%
Change (1 day)
-68.76%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): A$28.58

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is A$29.87. In 2025 the company made an earnings per share (EPS) of A$2.65.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$28.58976.93%
2025A$2.65
2023A-$5.32-62%
2022A-$14.0129.03%
2021A-$10.86-3.36%
2020A-$11.23-8.48%
2019A-$12.287.67%
2018A-$11.4039.74%
2017A-$8.1612.94%
2016A-$7.2238.84%
2015A-$5.20-32.88%
2014A-$7.75259.44%
2013A-$2.16-31.25%
2012A-$3.14

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
A$7.92-73.50%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$2.99-90.00%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
A$70.85 137.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
A-$3.97-113.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
A-$1.10-103.69%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
A-$0.29-100.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
A$0.68-97.73%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
A-$5.02-116.81%๐Ÿ‡บ๐Ÿ‡ธ USA